NWHXUDPQPYGHGI-GRARQNNCSA-N
C26H38F2N6O5 — CID 130418624
Data last refreshed: (MolForge compound catalog, from PubChem)
About NWHXUDPQPYGHGI-GRARQNNCSA-N
NWHXUDPQPYGHGI-GRARQNNCSA-N (PubChem CID 130418624) has the molecular formula C26H38F2N6O5 and a molecular weight of 552.62 g/mol. Its IUPAC name is tert-butyl N-[2-[(2R)-1-[[(3aS,4S,6R,6aR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl]-4,4-difluoropiperidin-2-yl]ethyl]carbamate.
Molecular Properties
| Compound Name | NWHXUDPQPYGHGI-GRARQNNCSA-N |
|---|---|
| PubChem CID | 130418624 |
| Molecular Formula | C26H38F2N6O5 |
| Molecular Weight | 552.62 g/mol |
| Exact Mass | 552.29 |
| IUPAC Name | tert-butyl N-[2-[(2R)-1-[[(3aS,4S,6R,6aR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl]-4,4-difluoropiperidin-2-yl]ethyl]carbamate |
| SMILES | CC(C)(C)OC(=O)NCC[C@@H]1CC(F)(F)CCN1C[C@H]1O[C@@H](c2ccc3c(N)ncnn23)[C@@H]2OC(C)(C)O[C@@H]21 |
| InChI | InChI=1S/C26H38F2N6O5/c1-24(2,3)39-23(35)30-10-8-15-12-26(27,28)9-11-33(15)13-18-20-21(38-25(4,5)37-20)19(36-18)16-6-7-17-22(29)31-14-32-34(16)17/h6-7,14-15,18-21H,8-13H2,1-5H3,(H,30,35)(H2,29,31,32)/t15-,18-,19+,20-,21+/m1/s1 |
| InChIKey | NWHXUDPQPYGHGI-GRARQNNCSA-N |
| XLogP | 3.29 |
| TPSA | 125.47 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 39 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 552.62 |
| LogP ≤ 5 | 3.29 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 130418624 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.